^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of low-dose afatinib combined with bevacizumab and pemetrexate in first-line treatment of stage IV lung adenocarcinoma with EGFR mutation
Excerpt:
...Gene test from tumor tissues confirmed EGFR mutation positive (including 19del, L858R, G719A, G719C, G719S, L861Q); 8. ...
Trial ID:
Source:
Title:
Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
Published date:
01/12/2021
Excerpt:
...patients with stage IV EGFR-mutated lung adenocarcinoma who received afatinib-containing therapies...afatinib + cetuximab (N=7), or afatinib + bevacizumab (N=2)...A PFS ≥ 6 months on osimertinib (N=5) was associated with a significantly greater PFS on afatinib-containing therapy compared to a PFS < 6 months on osimertinib...Afatinib containing therapies have modest activity in treating patients with EGFR-mutated lung adenocarcinoma after progression on osimertinib...
Source:
Title:
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
Published date:
10/23/2020
Excerpt:
...57 patients with advanced EGFR-mutated lung adenocarcinoma who received afatinib combined with bevacizumab as first-line therapy...The objective response rate and disease control rate of afatinib combined with bevacizumab therapy were 87.7% and 100%, respectively. In all patients, the median progression-free survival (PFS) and overall survival (OS) were 23.9 (95% confidence interval (CI) (17.56-29.17)) and 45.9 (95% CI (39.50-53.60)) months, respectively.
DOI:
10.3390/ph13110331
